XETRA - Delayed Quote EUR

Novavax, Inc. (NVV1.DE)

7.85

-0.04

(-0.53%)

As of February 17 at 5:35:45 PM GMT+1. Market Open.

Novavax First Quarter 2025 Earnings: Beats Expectations

Novavax ( NASDAQ:NVAX ) First Quarter 2025 Results Key Financial Results Revenue: US$666.7m (up by US$572.8m from 1Q...

Simply Wall St. 4 days ago

NVAX
Analysts Just Shipped An Incredible Upgrade To Their Novavax, Inc. (NASDAQ:NVAX) Estimates

Novavax, Inc. ( NASDAQ:NVAX ) shareholders will have a reason to smile today, with the analysts making substantial...

Simply Wall St. 5 days ago

NVAX
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2025.

PR Newswire 6 days ago

NVAX
Novavax to Participate in BofA Securities 2025 Health Care Conference

Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference.

PR Newswire 7 days ago

NVAX
Novavax (NasdaqGS:NVAX) And Takeda Amend Collaboration For SARS-CoV-2 Vaccine In Japan

Novavax (NasdaqGS:NVAX) recently amended its collaboration agreement with Takeda, enhancing its revenue potential through a new upfront payment structure and future royalties. These developments, along with the appointment of Charles Newton to the board, signal a strategic shift towards strengthening the company's market position. This comes at a time when the broader market has experienced moderate volatility, with minor shifts amid ongoing tariff discussions and a Federal Reserve meeting,...

Simply Wall St. 8 days ago

NVAX
Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

Novavax, Inc. (Nasdaq: NVAX) has updated the terms of the previously announced collaboration and licensing agreement (CLA) with Takeda. The improved financial terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid® in Japan include an upfront payment, payment related to the 2024/2025 season, annual milestones associated with regulatory approvals and royalties on net sales earned every season moving forward.

PR Newswire 9 days ago

NVAX
Novavax to Report First Quarter 2025 Financial Results on May 8, 2025

Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, May 8, 2025. Details of the event and replay are as follows:

PR Newswire 13 days ago

NVAX
Novavax Appoints Charles Newton to Board of Directors

Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors.

PR Newswire 15 days ago

NVAX
Nvidia & chip stocks falling, Novavax vaccine, Zscaler upgrade

Yahoo Finance host Julie Hyman takes a look at today's top moving stocks and biggest market stories in this segment of Market Minute, Semiconductor stocks (SOXX) are falling on reports that Huawei is developing a new artificial intelligence (AI) chip, rivaling Nvidia (NVDA). Novavax (NVAX) is in focus after the company responded to the FDA's call for an additional clinical trial for its COVID-19 vaccine. Zscaler (ZS) was upgraded to Outperform from Neutral by BNP Paribas. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Yahoo Finance Video 16 days ago

ZS

NVDA

NVAX
Trending tickers: Deliveroo, Reliance, Toyota, Novavax and M&S

The latest investor updates on stocks that are trending on Monday

Yahoo Finance UK 16 days ago

DLVEY

DROOF

^DJI
FDA Asks Vaccine Maker to Complete New Clinical Trial for Delayed Covid-19 Shot

The additional step, which could cost millions of dollars, goes beyond what other Covid-19 vaccine makers had to do to win approval.

The Wall Street Journal 19 days ago

NVAX
Novavax (NasdaqGS:NVAX) Announces Positive SHIELD-Utah Study Results

Novavax (NasdaqGS:NVAX) recently announced preliminary results from its SHIELD-Utah study, showcasing the Novavax COVID-19 vaccine's effectiveness and reduced side effects compared to a competitor's vaccine. This positive announcement aligns with a 17.8% increase in the company's share price last week. The broader market was also on an upward trend, with indices gaining noticeably over the same period. While the details from Novavax's study can potentially bolster investor confidence and...

Simply Wall St. 19 days ago

NVAX
Vertiv earnings beat, DOJ & Disney–fuboTV deal, Novavax COVID shot

Brad Smith outlines the top stories on Wall Street as part of Yahoo Finance's Market Minute. Vertiv Holdings (VRT) stock is soaring after the company reported first quarter earnings that beat Wall Street estimates and increased its full-year guidance, signaling strong artificial intelligence (AI) demand. The US Department of Justice is looking into Disney's (DIS) deal with fuboTV (FUBO) for possible antitrust concerns. Novavax (NVAX) stock surges after the US Food and Drug Administration (FDA) requested COVID vaccine data from the company, which could signal that FDA approval is incoming. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Yahoo Finance Video 21 days ago

DIS

VRT

FUBO
Novavax Jumps After FDA Asks for More Data on Its Covid Vaccine

(Bloomberg) -- Novavax Inc. shares rose after US regulators asked for more data on its Covid vaccine, signaling the shot may be on a path to full approval despite US Health and Human Services Secretary Robert F. Kennedy Jr. raising doubts about its efficacy. Most Read from BloombergTrump Gives New York ‘One Last Chance’ to End Congestion FeeDOGE Visits National Gallery of Art to Discuss Museum’s Legal StatusThe Racial Wealth Gap Is Not Just About MoneyWhy Car YouTuber Matt Farah Is Fighting for

Bloomberg 21 days ago

NVAX
Novavax (NasdaqGS:NVAX) Study Shows Reduced Symptoms With New COVID-19 Vaccine Formula

Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, Adjuvanted, compared to Pfizer-BioNTech's offering. Despite this positive development, the company's stock performance last week was largely flat, rising 1%, amid broader market fluctuations driven by U.S. restrictions on chip exports to China. The Dow Jones, S&P 500, and Nasdaq all experienced notable...

Simply Wall St. 28 days ago

NVAX
SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA

Novavax, Inc. (Nasdaq: NVAX) today announced preliminary results from the SHIELD-Utah study (Study of Healthcare Workers and First Responders Investigating Effects of Systemic and Local reactogenicity of COVID-19 Vaccine Doses in Utah) that showed Novavax's COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) targeting the JN.1 strain resulted in fewer and less severe reactogenicity symptoms, when compared with the Pfizer-BioNTech mRNA 2024-2025 vaccine. This real-world study conducted between Septe

PR Newswire 29 days ago

NVAX
Novavax slides after RFK Jr. casts doubts about COVID vaccine

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay. The Secretary of Health and Human Services pointed to the vaccine’s single-antigen composition as the reason for the push back, adding that the FDA is “shifting our priorities to multiple-antigen vaccines.” SHIFTING PRIORITIES: The Food and Drug Administration is sitting on the decision to grant full approval for Novavax COVID-19 shot. In an interview wit

TipRanks last month

PFE

NVAX

MRNA
Nike, Disney, Novavax: Trending Tickers

Julie Hyman and Josh Lipton take a closer look at some of Thursday's trending tickers on Market Domination. Tariff risks weigh on Nike (NKE) as US President Trump increases the tariff on imports from China to 145%. Entertainment stocks like Disney (DIS), Warner Bros. Discovery (WBD), and Fox (FOX, FOXA) are falling after China cut imports of Hollywood content. Novavax (NVAX) stock plunges after US Health and Human Services Secretary Robert F. Kennedy Jr. questioned the efficacy of the company's vaccines. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video last month

FOX

FOXA

WBD
Novavax & RFK Jr., Costco sales, Lovesac earnings: Market Minute

Josh Lipton explores some of the top stories on Yahoo Finance's Market Minute. Novavax (NVAX) shares fell after US President Donald Trump's Secretary of Health and Human Services Robert F. Kennedy Jr. questioned the efficacy of the company's COVID vaccine. Costco's (COST) March comparable sales beat estimates. Lovesac (LOVE) reported fourth quarter results, with sales beating estimates. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Yahoo Finance Video last month

COST

LOVE

NVAX
Novavax (NasdaqGS:NVAX) Announces Leadership Change With New Board Appointments

Novavax (NasdaqGS:NVAX) experienced a noteworthy 13% increase in its share price last week, coinciding with significant changes in its leadership. The retirement of James Young as Chair of the Board and the appointment of Margaret McGlynn, along with the addition of John Shiver as an independent director, signify a phase of strategic development focused on vaccine innovation. This positive momentum for Novavax was more noticeable against a broader market backdrop where major indexes, spurred...

Simply Wall St. last month

NVAX

Performance Overview

Return	NVV1.DE	S&P 500 (^GSPC)
YTD	-5.53%	+0.19%
1-Year	-5.53%	+12.31%
3-Year	-5.53%	+46.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novavax, Inc. (NVV1.DE)

Novavax First Quarter 2025 Earnings: Beats Expectations

Analysts Just Shipped An Incredible Upgrade To Their Novavax, Inc. (NASDAQ:NVAX) Estimates

Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

Novavax to Participate in BofA Securities 2025 Health Care Conference

Novavax (NasdaqGS:NVAX) And Takeda Amend Collaboration For SARS-CoV-2 Vaccine In Japan

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

Novavax to Report First Quarter 2025 Financial Results on May 8, 2025

Novavax Appoints Charles Newton to Board of Directors

Nvidia & chip stocks falling, Novavax vaccine, Zscaler upgrade

Trending tickers: Deliveroo, Reliance, Toyota, Novavax and M&S

FDA Asks Vaccine Maker to Complete New Clinical Trial for Delayed Covid-19 Shot

Novavax (NasdaqGS:NVAX) Announces Positive SHIELD-Utah Study Results

Vertiv earnings beat, DOJ & Disney–fuboTV deal, Novavax COVID shot

Novavax Jumps After FDA Asks for More Data on Its Covid Vaccine

Novavax (NasdaqGS:NVAX) Study Shows Reduced Symptoms With New COVID-19 Vaccine Formula

SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA

Novavax slides after RFK Jr. casts doubts about COVID vaccine

Nike, Disney, Novavax: Trending Tickers

Novavax & RFK Jr., Costco sales, Lovesac earnings: Market Minute

Novavax (NasdaqGS:NVAX) Announces Leadership Change With New Board Appointments

Performance Overview